Status:
COMPLETED
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
Lead Sponsor:
Danish HIV Research Group
Collaborating Sponsors:
Odense University Hospital
Rigshospitalet, Denmark
Conditions:
HIV Associated Lipodystrophy Syndrome.
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological al...
Eligibility Criteria
Inclusion
- Currently treated with lamivudine, zidovudine and abacavir
- Viral load \< 200 copies/ml
- Ability to understand and provide written informed consent.
Exclusion
- Women being pregnant or breast-feeding.
- Fertile women using no safe contraception.
- Patients with active intravenous drug use.
- Abuse of alcohol, which in the opinion of the treating physician will reduce the patient´s ability to follow a therapeutic regimen and evaluations of the protocol.
- Creatinine \> 200 mmol/l.
- ALT or AST \> 5 times upper normal value (200U/l).
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00139178
Start Date
March 1 2004
End Date
April 1 2007
Last Update
September 5 2005
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Diseases, Aarhus University Hospital
Aarhus, Denmark, 8200
2
Department of Infectious Diseases, Rigshospitalet
Copenhagen, Denmark, 2100
3
Department of Infectious Diseases, Hvidovre University Hospital
Hvidovre, Denmark, 2650
4
Department of Infectious diseases, Odense University Hospital
Odense, Denmark, 5000